Anika Therapeutics (ANIK) executive compensation, 2026 proxy

Cheryl R. Blanchard, Ph.D., Executive Chair; Former President and Chief Executive Officer, was paid $4.9M in 2025, down 4% from $5.1M the year before. The CEO-to-median-employee pay ratio was 44:1, on median employee pay of $112,114.

Filed
April 28, 2026
Annual meeting
June 18, 2026
Pay year
2025
Named executives
5
CEO total pay
$4.9M-4% vs prior year
CEO to median employee
44:1median $112,114
CEO pay in equity
71%$3.5M in awards
Total Revenue
$112.8MFor fiscal year 2025
Operating Cash Flow
$11.2MDemonstrated improved operational discipline
Free Cash Flow
$4.4MWorking capital management
Employee Population
238Total individuals as of Dec 31, 2025

How Ph.D. was paid

$4.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary15%Bonus13%Stock awards71%All other compensation0%

Named executive officers

ExecutiveTotal
Cheryl R. Blanchard, Ph.D.Executive Chair; Former President and Chief Executive Officer$4,887,318
Stephen D. GriffinPresident and Chief Executive Officer; Former EVP, Chief Financial Officer and Chief Operating Officer$2,033,370
David B. ColleranEVP, General Counsel and Secretary$1,614,205
Anne M. NunesFormer SVP, Chief Operations Officer$946,571
Ian W. McLeodSVP, Chief Accounting Officer and Treasurer$765,544

What changed and why

  • $112.8MGenerated total revenue of $112.8 million for the year while maintaining a focused cost structure.
  • $11.2MDelivered $11.2 million of operating cash flow and $4.4 million of free cash flow in 2025.
  • $4.9MDr. Blanchard received total compensation of $4,887,318 in fiscal year 2025.
  • Stephen D. Griffin succeeded Dr. Blanchard as President and Chief Executive Officer in February 2026.
  • The ratio of the annual total compensation of the CEO to the median employee was 44 to 1.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.